Complete and Durable Responses in R/R ALL Patients Treated with VNX-101 Announced
“While early, these results are highly encouraging after delivering just a single, off-the-shelf administration of VNX-101, which enables the body to produce a CD19/CD3 T-cell–engaging protein,” said Samit Varma, Chief Executive Officer of Vironexis. “These three patients have tried multiple lines of therapy and, sadly, exhausted available treatment options. We believe the depth, consistency, and emerging durability of these responses provide important clinical validation of our in vivo therapeutic proteinplatform, and compelling proof of concept for its potential to transform the body into a meaningful, durable source of highly active cancer therapeutics.”
Share:
More News
Jian Peng, PhD, CEO of Earendil Labs, said: “Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development—from predictive protein modeling and generative protein design to rapid experimental validation. By combining
“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have
“These Phase 3 results reinforce the potential of ZENBEXUS to advance treatment for patients with relapsed or refractory multiple myeloma,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As the first therapy in multiple myeloma to demonstrate superiority on an MRD-negative complete
“Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA‑17 programme,” said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. “With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will